Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Len Neckers

Showing results (111-120 of 168) with videos related to

Pageof 17
Sort By:
Molecular Cancer Therapeutics|May 14, 2004
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activityEdward G Mimnaugh, Wanping Xu, Michele Vos, et al.
Oncotarget|February 2, 2013
TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cellsDimitra Bourboulia, HuiYing Han, Sandra Jensen-Taubman, et al.
Cancer Research|November 25, 2003
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cellsWanping Xu, Xitong Yuan, Yun Jin Jung, et al.
Journal of Chemical Theory and Computation|December 1, 2015
Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for the C-terminal Domain of Hsp90Giulia Morra, Marco A C Neves, Christopher J Plescia, et al.
The EMBO Journal|May 15, 2002
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapyAmi Citri, Iris Alroy, Sara Lavi, et al.
The Journal of Clinical Investigation|February 21, 2009
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90Byoung Heon Kang, Janet Plescia, Ho Young Song, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 26, 2009
Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligaseElana S Ehrlich, Tao Wang, Kun Luo, et al.
Plos One|March 5, 2013
Targeting heat shock protein 90 for the treatment of malignant pheochromocytomaAlessio Giubellino, Carole Sourbier, Min-Jung Lee, et al.
Oncotarget|September 10, 2016
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcomaChristine M Heske, Arnulfo Mendoza, Leah D Edessa, et al.
Journal of Medicinal Chemistry|September 19, 2013
Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulatorsAntonella Pepe, Michael Pamment, Yeong Sang Kim, et al.
Pageof 17

Showing results (111-120 of 168) with videos related to

Sort By:
Pageof 17
Molecular Cancer Therapeutics|May 14, 2004
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activityEdward G Mimnaugh, Wanping Xu, Michele Vos, et al.
Oncotarget|February 2, 2013
TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cellsDimitra Bourboulia, HuiYing Han, Sandra Jensen-Taubman, et al.
Cancer Research|November 25, 2003
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cellsWanping Xu, Xitong Yuan, Yun Jin Jung, et al.
Journal of Chemical Theory and Computation|December 1, 2015
Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for the C-terminal Domain of Hsp90Giulia Morra, Marco A C Neves, Christopher J Plescia, et al.
The EMBO Journal|May 15, 2002
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapyAmi Citri, Iris Alroy, Sara Lavi, et al.
The Journal of Clinical Investigation|February 21, 2009
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90Byoung Heon Kang, Janet Plescia, Ho Young Song, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 26, 2009
Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligaseElana S Ehrlich, Tao Wang, Kun Luo, et al.
Plos One|March 5, 2013
Targeting heat shock protein 90 for the treatment of malignant pheochromocytomaAlessio Giubellino, Carole Sourbier, Min-Jung Lee, et al.
Oncotarget|September 10, 2016
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcomaChristine M Heske, Arnulfo Mendoza, Leah D Edessa, et al.
Journal of Medicinal Chemistry|September 19, 2013
Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulatorsAntonella Pepe, Michael Pamment, Yeong Sang Kim, et al.
Pageof 17